Publications

cemka > Publications

Classer les publications sur l'année

  • Économie de la santĂ©

    Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France

    FERNANDEZ H, JOURDAIN O, VILLEFRANQUE V, LEHMANN M, LAFUMA A, TRANCART M.

    BMJ Open ; 2017;7(9):e015571

  • Économie de la santĂ©

    Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.

    CLAUDEPIERRE P, FAGNANI F, CUKIERMAN G, DE CHALUS T, JOUBERT JM, LAURENDEAU C, GOURMELEN J, BREBAN M

    Joint Bone Spine ; 2019;86(1);69-75

  • Pharmaco-EpidĂ©miologie

    Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting.

    BARBUT F, GALPERINE T, VANHEMS P, LE MONNIER A, DURAND-GASSELIN B, CANIS F, JEANBAT V, DUBURCQ A, ALAMI S, BENSOUSSAN C, FAGNANI F.

    Health Qual Life Outcomes ; 2019;17(1);6

  • Économie de la santĂ©

    Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)

    BOUAME M, ALI LAHMAR M, BOUAFIA MT, HAMMOUDI N, CHENTIR MT, ATHMANE MA, KARA S, TRANCART M, YILDIZ L, CHEYNEL J, SOUALMI R.

    J Med Econ ; 2018; 21(12):1213-1220

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.

    AGOSTINI A, GODARD C, LAURENDEAU C, BENMAHMOUD ZOUBIR A, LAFUMA A, LÉVY-BACHELOT L, GOURMELEN J, LINET T.

    Eur J Contracept Reprod Health Care ; 2018;23(6):421-426

  • SantĂ© publique

    Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France.

    GOZLAN G, LECARDEUR L, MONFORT AS, DOZ M, ORTIZ I, LARROUMETS P, LAFUMA A.

    Encephale ; 2018 ;44(6):496-503.

  • Market Access

    Clinical added value of drugs : An empirical survey of French transparency committee opinions.

    DETOURNAY B, BOREL T, TRANCART M, EMERY C, COUDRAY-OMNES C, LEEM WORKING GROUP ONHEALTH TECHNOLOGY ASSESSMENT OF DRUGS.

    Thérapie ; 2018;S0040-5957(18)30245-2

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database

    DALLONGEVILLE J, SACHER F, BOUEE S , EMERY C, BUREAU I, GOURMELEN J, FAUCHIER L.

    Therapie ; 2018;73:449-460

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study

    DEFER G, DE SEZE J, BOUEE S, COUROUVE L, LONGIN J, PAYET M, JEAN DELEGLISE A.S, THE STUDY GROUP

    Multiple Sclerosis and Related Disorders ; 2018;25:276-281

  • SantĂ© publique

    Facteurs associĂ©s au maintien dans le poste de travail aprĂšs un Ă©pisode d’absence : rĂ©sultats de l’étude MAPOST des mĂ©decins du travail du groupe La Poste.

    DUBURCQ A, COUROUVE L, HAVETTE P, DAB W & Le Comité Des Médecins Du Travail De La Poste

    Archives des Maladies Professionnelles et de l'Environnement ; 2018,79(6);705-716

  • Économie de la santĂ©

    Modelling lifetime cost consequences of toric compared with standard IOLs in cataract surgery of astigmatic patients in four European countries

    LAURENDEAU C, LAFUMA A, BERDEAUX G

    J Med Economics ; 12(3):230-237

  • Pharmaco-EpidĂ©miologie

    Screening to detect permanent childhood hearing impairment in neonates transferred from the newborn nursery

    DAUMAN R, ROUSSEY M, BELOT V, DENOYELLE F, ROMAN S, GAVILAN-CELLIÉ I, RUZZA-SURROCA I, CALMELS MN, LINA-GRANADE G, HOUSSIN E, CHARLEMAGNE A, GARABEDIAN N

    Int J Pediatr Otorhinolaryngol ; 73(3):457-465

  • SantĂ© publique

    Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à 2001

    ROBERT J, ROUDIER C, POUTIGNAT N, FAGOT-CAMPAGNA A, WEILL A, RUDNICHI A, THAMMAVONG N, FONTBONNE A, DETOURNAY B

    Bull Epidemiol Hebd ; 42-43:455-460

  • Pharmaco-EpidĂ©miologie

    Prevalence of diagnosed type 2 diabetes mellitus in the French general population : The INSTANT study

    BRINGER J, FONTAINE P, DETOURNAY B, NACHIT-OUINEKH F, BRAMI G, ESCHWEGE E

    Diabetes Metab ; 35(1):25-31

  • Pharmaco-EpidĂ©miologie

    Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France.

    PINQUIER D, GOUYON JB, FAUROUX B, MONS F, VICAUT E, BENDJENANA H, ROUFFIAC E, MARRET S, AUJARD Y.

    Arch Pediatr. ; 16(11):1443-1452